A pharmaco-metabonomic study on chronic kidney disease and therapeutic effect of Ergone by UPLC-QTOF/HDMS

Medicine & Life Sciences

• ergosta-4,6,8(14),22-tetraen-3-one 100%
• Metabolomics 54%
• Chronic Renal Insufficiency 45%
• Therapeutic Uses 40%
• Biochemistry 14%
• Adenine 12%
• purine 12%
• Fatty Acids 9%
• Proteins 8%
• Amino Acids 7%
• Least-Squares Analysis 6%
• Time-to-Treatment 6%
• Oral Administration 4%
• Collagen 4%
• Public Health 3%
• Down-Regulation 3%
• Western Blotting 3%
• Pharmacology 3%
• Biomarkers 3%
• Control Groups 2%
• Serum 2%

Agriculture & Biology

• kidney diseases 63%
• metabolomics 50%
• therapeutics 38%
• blood chemistry 18%
• fatty acid metabolism 13%
• amino acid metabolism 12%
• protein synthesis 12%
• adenine 11%
• purines 11%
• nephroprotective effect 9%
• metabolites 7%
• pharmacology 6%
• metabolism 6%
• histopathology 6%
• oral administration 5%
• least squares 5%
• public health 5%
• biochemistry 5%
• biomarkers 4%
• collagen 4%
• Western blotting 4%
• proteins 1%

Chemical Compounds

• Pharmacological Metabolism 38%
• Purine 16%
• Nephroprotective 15%
• Protein 13%
• Fatty Acid 13%
• Metabolite 11%
• Collagen 7%
• Biological Marker 7%
• Metabolic 6%
• Acid 5%